BrightGene Bio-Medical Technology Co., Ltd. (688166) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

BrightGene Bio-Medical Technology Co., Ltd.

Why is BrightGene Bio-Medical Technology Co., Ltd. ?

High Debt Company with a Debt to Equity ratio (avg) at times

Poor long term growth as Net Sales has grown by an annual rate of 11.00% and Operating profit at -25.90% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times
The company has been able to generate a Return on Equity (avg) of 9.15% signifying low profitability per unit of shareholders funds

Poor long term growth as Net Sales has grown by an annual rate of 11.00% and Operating profit at -25.90% over the last 5 years

The company has declared negative results for the last 6 consecutive quarters

NET PROFIT(HY) At CNY 37.56 MM has Grown at -65.94%
OPERATING CASH FLOW(Y) Lowest at CNY 210.71 MM
NET SALES(9M) At CNY 874.25 MM has Grown at -10.36%

With ROE of 2.57%, it has a very expensive valuation with a 9.92 Price to Book Value

Over the past year, while the stock has generated a return of 19.88%, its profits have fallen by -60.5%
At the current price, the company has a high dividend yield of 0.2

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is BrightGene Bio-Medical Technology Co., Ltd. for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

BrightGene Bio-Medical Technology Co., Ltd.

15.26%

0.36

58.00%

China Shanghai Composite

15.17%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

11.00%

EBIT Growth (5y)

-25.90%

EBIT to Interest (avg)

25.45

Debt to EBITDA (avg)

3.56

Net Debt to Equity (avg)

0.57

Sales to Capital Employed (avg)

0.26

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

21.42%

Pledged Shares

Institutional Holding

ROCE (avg)

7.70%

ROE (avg)

9.15%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

386

Industry P/E

Price to Book Value

9.92

EV to EBIT

310.42

EV to EBITDA

112.54

EV to Capital Employed

6.41

EV to Sales

22.71

PEG Ratio

Dividend Yield

0.17%

ROCE (Latest)

2.07%

ROE (Latest)

2.57%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

NET SALES(Q)

Highest at CNY 336.81 MM

PRE-TAX PROFIT(Q)

At CNY 32.37 MM has Grown at 91.23%

-27What is not working for the Company

NET PROFIT(HY)

At CNY 37.56 MM has Grown at -65.94%

OPERATING CASH FLOW(Y)

Lowest at CNY 210.71 MM

NET SALES(9M)

At CNY 874.25 MM has Grown at -10.36%

ROCE(HY)

Lowest at 2.59%

RAW MATERIAL COST(Y)

Grown by 8.04% (YoY

DEBT-EQUITY RATIO (HY)

Highest at 77.64 %

INTEREST(Q)

Highest at CNY 19.34 MM

Here's what is working for BrightGene Bio-Medical Technology Co., Ltd.

Net Sales

Highest at CNY 336.81 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Net Sales

At CNY 336.81 MM has Grown at 15.91%

over average net sales of the previous four periods of CNY 290.58 MM

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Pre-Tax Profit

At CNY 32.37 MM has Grown at 91.23%

over average net sales of the previous four periods of CNY 16.93 MM

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Here's what is not working for BrightGene Bio-Medical Technology Co., Ltd.

Net Profit

At CNY 37.56 MM has Grown at -65.94%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CNY MM)

Operating Cash Flow

Lowest at CNY 210.71 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Interest

At CNY 19.34 MM has Grown at 37.63%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Interest

Highest at CNY 19.34 MM

in the last five periods and Increased by 37.63% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio

Highest at 77.64 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost

Grown by 8.04% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales